A Phase I Study To Evaluate Psca-Targeting Chimeric Antigen Receptor (Car)-T Cells For Patients With Psca Plus Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
JOURNAL OF CLINICAL ONCOLOGY(2020)
摘要
TPS250Background: Although treatment options have improved, mCRPC remains highly lethal. Immunotherapy holds potential for durable remissions but not yet in mCRPC. CAR-T cell therapy has yielded cu...
更多查看译文
关键词
chimeric antigen receptor,mcrpc,prostate,psca-targeting,castration-resistant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要